A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Placebo Added to Metformin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Monotherapy
Phase: PHASE3
Conditions: Type 2 Diabetes Mellitus
Sponsor: Lexicon Pharmaceuticals

Official Title: A 52-week Randomized, Double-blind, Double-dummy, Active- and 
Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the 
Efficacy and Safety of Sotagliflozin compared to Glimepiride or 
Placebo Added to Metformin in Patients with Type 2 Diabetes who 
have Inadequate Glycemic Control with Metformin Monotherapy 
NCT Number: NCT03332771 
Document Date: Protocol Version 2: 11-April-2018